Olaparib Protects Patients From High-Risk Cancer Recurrences

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first patient in the phase 3 OlympiA trial was enrolled.
Medscape Medical News